Search
for
Sort by
Research 61–90 of 1000+
- A study of COVID‐19 vaccine (Covishield) induced dermatological adverse effects from India
- A rare complication of follicular hair unit extraction: Kaposi’s varicelliform eruption
- Isomorphic and isotopic phenomenon occurring simultaneously in a case of granuloma annulare
- Cutaneous Adverse Drug Reactions (CADRs) to COVID19 vaccines: A case series
- Diagnosis of stress-associated dermatologic conditions in New York City safety-net hospitals during the COVID-19 pandemic
- Social isolation: main dermatosis and the impact of stress during the COVID-19 pandemic
- Dermatology Issues in Sports
- Male‐pattern baldness, common latent viruses, and microcompetition
- Effects of Wet Cupping on Blood Components Specially Skin-Related Parameters of Healthy Cases: A Case Control Metabonomic Study
- A CLINICAL STUDY OF MUCOCUTANEOUS MANIFESTATIONS OF HIV
- [Mycophenolate mofetil in induction and maintenance therapy for juvenile onset severe lupus nephritis].
- Seasonal Patterns and Trends in Dermatoses in Poland
- Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Cutaneous manifestations associated with COVID-19 infection at a university hospital in eastern China
- Beard Alopecia: An Updated and Comprehensive Review of Etiologies, Presentation and Treatment
- Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
- Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin
- Cutaneous Manifestations of COVID-19
- Hair and Scalp Infections
- DENOUEMENT—CONTINUED FROM P. 661
- Janus Kinase (JAK) Inhibitors in Dermatology: An Update and Critical Review
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Shared Spaces: Decoding Dual Dermatoses in a Single Dermatome
- Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark
- Autologous Mini Punch Graft in Vitiligo: A Narrative Review
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- A clinical study of Geriatric dermatoses at Tertiary care center in South India
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
- Dermatological manifestations associated with COVID‐19 and COVID‐19 vaccination: results from the Lebanese COVID registry